BioSpace News Archive

StemExpress, a Folsom, California headquartered biotechnology company is now providing critical COVID-19 testing capabilities to Sierra Donor Services (SDS), the federally designated Organ Procurement Organization (OPO) headquartered in Sacramento, CA

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that it has dosed the first patient in VANGARD, a potentially pivotal Phase 2 clinical trial to evaluate PB1046 as a treatment for hospitalized COVID-19 patients who are at high risk for rapid clinical deterioration and acute respiratory distress syndrome (ARDS).

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), recently established the COVID-19 Prevention Network (CoVPN). I

BioConsortia, Inc., innovator of microbial solutions in crop protection, soil fertility, and yield improvement, welcomes Dr. Damian Curtis to the company as Director of Synthetic Biology and Genomics.

BioSig Technologies, Inc., a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, announced that its Board of Directors had adopted a stockholder Rights Agreement.

A NEW breast cancer drug shown to significantly reduce the risk of cancer recurrence is now approved for use in Malaysia.

Berkeley Lights, Inc., a leader in Digital Cell Biology, today announced the pricing of its initial public offering of 8,100,000 shares of common stock at a public offering price of $22.00 per share.

Boston Strategic Partners study shows ‘Fusion by Paradigm’ reduces implant costs by 25 percentage points more than typical industry outcomes

CareDx, Inc., a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced that it will release financial results for the second quarter 2020 after the close of trading on Tuesday, August 4, 2020.

Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that its partner, Sunovion Pharmaceuticals Canada Inc., has received approval from Health Canada to market oral and intravenous (IV) formulations of XENLETA® (lefamulin) for the treatment of community-acquired pneumonia (CAP) in adults.